Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9457440 | 0.81 | HSD11B1 (0.46) | ALDH1A1MMP2CA1CA2MMP1 | |
| SCHEMBL571463 | 0.81 | MMP2 (0.43) | ALDH1A1MAPK1MMP2CA1CA2 | |
| SCHEMBL14194257 | 0.80 | MMP2 (0.46) | ALDH1A1MAPK1MMP2CA1CA2 | |
| SCHEMBL517720 | 0.80 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL10146079 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MAPK1SMN1; SMN2MMP2CA1 | |
| SCHEMBL9489943 | 0.79 | CA1 (0.42) | ALDH1A1MAPK1MMP2CA1CA2 | |
| SCHEMBL1156438 | 0.78 | LMNA (0.50) | ALDH1A1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL7940614 | 0.78 | MMP2 (0.45) | ALDH1A1HTTMMP2CA1CA2 | |
| SCHEMBL1098294 | 0.78 | LMNA (0.50) | ALDH1A1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL1098295 | 0.78 | GAA (0.54) | ALDH1A1LMNAMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| CN-114072000-A | Molecules having certain pesticidal effects and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3452461-B1 | PIPERIDINES AS MENIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190152947-A1 | PIPERIDINES AS MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-23 | — | — | US | disclosed |
| WO-2017192543-A1 | PIPERIDINES AS MENIN INHIBITORS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-3043784-A1 | ARYL ETHERS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015035223-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-6242654-B1 | REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
| EP-0365763-A1 | Antiproliferative cyclic compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | MEN1, WFS1, BRCA1 | ALDH1A1 1686/4885LMNA 579/4885MAPK1 3185/4885 |
| US-20190152947-A1 | PIPERIDINES AS MENIN INHIBITORS | MEN1, GDI2, GNAQ | ALDH1A1 1653/4885LMNA 577/4885MAPK1 2805/4885 |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | PTDSS1, PTDSS2, SMPD1 | ALDH1A1 2761/4885LMNA 4163/4885MAPK1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.